Kaliberr Bioscience Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 22-12-2024
- Paid Up Capital ₹ 1.00 M
as on 22-12-2024
- Company Age 4 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 23.50 Cr
as on 22-12-2024
- Revenue %
(FY 2022)
- Ebitda
- Net Worth 978.25%
(FY 2022)
- Total Assets 327.60%
(FY 2022)
About Kaliberr Bioscience
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹23.50 Cr.
Madhu Ramadugu, Sushant Bhandari, and Madhusudan Bhandari serve as directors at the Company.
- CIN/LLPIN
U24230MH2020PTC339937
- Company No.
339937
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 May 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Nashik, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Kaliberr Bioscience?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sushant Bhandari  | Director | 23-May-2020 | Current |
| Madhu Ramadugu | Director | 18-Jun-2020 | Current |
| Madhusudan Bhandari | Director | 23-May-2020 | Current |
Financial Performance of Kaliberr Bioscience.
Kaliberr Bioscience Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth Soared by an impressive increase of 978.25%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Kaliberr Bioscience?
In 2022, Kaliberr Bioscience had a public holding of 90.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Hospitalis Supply Solutions Private LimitedActive 12 years 3 months
Madhu Ramadugu is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 17 Jul 2023 | ₹6.00 Cr | Open |
Hdfc Bank Limited Creation Date: 20 Jun 2022 | ₹17.50 Cr | Open |
How Many Employees Work at Kaliberr Bioscience?
Kaliberr Bioscience has a workforce of 84 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kaliberr Bioscience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kaliberr Bioscience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
